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tAbstract  
Clinical trial enrichment involves prospectively incorporating trial design elements that increase 
the probability of detecting a treatment effect. The use of enrichment strategies in pediatric drug 
development has not been systematically assessed. We analyzed the use of enrichment strategies 
in pediatric trials submitted to the US Food and Drug Administration from 2012-2016. One 
hundred twelve efficacy studies associated with 76 drug development programs were assessed 
and their overall success rates were 78% and 75% respectively.  Eighty-eight trials (76.8%) 
employed at least one enrichment strategy; of these, 66.3% employed multiple enrichment 
strategies. The highest trial success rates were achieved when all three enrichment strategies 
(practical, predictive, and prognostic) were used together within a single trial (87.5%), while the 
lowest success rate was observed when no enrichment strategy was used (65.4%). The use of 
enrichment strategies in pediatric trials was found to be associated with trial and program success 
in our analysis. 
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tIntroduction 
Designing clinical trials to include patient populations most likely to demonstrate a response to 
the therapy being studied is not a new concept.  The term “enrichment” refers to the prospective 
incorporation of clinical trial design elements intended to maximize the likelihood of observing a 
drug’s treatment effect (if, in fact, the drug is effective), and has been a focus area of the US 
Food and Drug Administration (FDA) since 1994.(1, 2) Enrichment strategies have been 
promulgated by FDA over the ensuing decades, culminating in the 2012 FDA Guidance for 
Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and 
Biological Products.(3) A variety of enrichment strategies exist, including those intended to 1) 
reduce non-drug-related variability (practical enrichment); 2) increase the incidence of clinical 
events of interest (prognostic enrichment); or 3) select patients most likely to respond to 
treatment (predictive enrichment).  All of these maneuvers are intended to increase study power 
to detect an investigational drug’s treatment effect.  Enrichment may, therefore, be particularly 
valuable when there are a limited number of patients available for study, or when there have 
been difficulties in achieving successful clinical trials for a therapeutic indication. Both 
situations fit pediatric drug development today. 
 Pediatric drug development is a relatively new science. The Best Pharmaceuticals for 
Children Act (BPCA) in 2002 and the Pediatric Research Equity Act (PREA) in 2003 were 
essentially the starting point for what has become a significant effort by drug developers and 
regulatory agencies to test new products in pediatric patients. The FDA has now received results 
from well over 1,000 pediatric clinical trials.  Many of these trials fail to show treatment benefit 
in the pediatric population, resulting in inability to approve the tested drugs for pediatric use. In 
one systematic review of studies submitted to the FDA from 1998 - 2012 for which sponsors 
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twere seeking pediatric exclusivity, 42% of pediatric drug development studies failed(4), and 
there are multiple reasons as to why these trials failed.(5) Optimizing enrichment strategies for 
pediatric trials appears to be a reasonable approach to increase trial success rates.  In fact, in 
some pediatric diseases, enrichment has been one method of turning an area with failed trials into 
an area of successful pediatric drug development.(6, 7)  A systematic evaluation of enrichment 
strategy approaches in pediatric drug development trials has not been performed to date.  The 
objectives of this analysis are to describe the use of enrichment strategies in pediatric drug 
development trials submitted to the FDA from 2012-2016 and assess the impact of enrichment 
on trial outcome and pediatric drug approval.   
Results 
Under FDASIA, 116 pediatric efficacy studies were identified, and 112 studies had all 
materials, including the pediatric protocols, available at the time of review.  The 112 studies 
were associated with 76 pediatric drug development programs, with some programs involving 
more than one pediatric trial (range 1-4).  The therapeutic areas and related approval rates for 
both trials and programs are summarized in Table 2.  There was a range of success rates at both 
the clinical trial and drug development program levels.  The overall success rate across 
therapeutic areas at the trial and program levels were 78% (median 81.8% and interquartile range 
[IQR] 53.4%) and 75% (median 80.8% and IQR 35.4%), respectively. Of the 76 programs, 42 
(55.3%) used at least one prognostic strategy, 30 (39.5%) used at least one practical strategy, and 
27 (35.5%) used at least one predictive strategy.  Table 3 lists the therapeutic areas, enrichment 
strategies used, and trial outcome. Overall, prognostic strategies constituted the most frequently 
used strategy (41.5%), followed by practical (30.8%) and predictive (27.7%) strategies. 
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clinical trials evaluated, a large majority (76.8%) employed at least one enrichment strategy.  Of 
the studies that employed enrichment strategies (n=86), 66.3% employed multiple enrichment 
strategies, while 33.7% used a single-enrichment approach.  In clinical trials where only one, 
enrichment strategy was used, the most common strategy was prognostic enrichment (44.8%), 
followed by predictive enrichment (37.9%), and practical enrichment (17.3%).  In trials that used 
multiple enrichment strategies, the highest success rates were achieved when all three 
enrichment strategies were used together (87.5%) compared with when two strategies were used 
(clinical trial success rate range 75% - 79.2%).  Of particular note, the lowest clinical trial 
success rate was observed when no enrichment strategy was used (65.4% vs. 81.4% for use of 
any enrichment strategy). 
Discussion 
The need for pediatric patient access to safe and effective FDA-approved medications has 
been long recognized and served as a major impetus for BPCA and PREA.  Since the passage of 
these laws, there has been increased attention to 1) root causes of failure in pediatric drug 
development; and 2) approaches to increase the probability of pediatric clinical trial and drug 
development program success.  Clinical trial enrichment represents a powerful strategy for 
selecting a subset of the general population in which the effect of the drug can be more 
efficiently demonstrated.  This approach has the potential to result in smaller studies, increased 
study power, and/or shortened drug development times. As such, enrichment is particularly 
attractive for pediatric drug development studies which are often plagued with small disease 
populations, enrollment challenges, and a relatively high failure rate of establishing efficacy.  
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development study, utilizing trial design tactics, such as enrichment, that offer the highest 
prospect of trial success is critical.  To our knowledge this is the first study to systematically 
evaluate the use of enrichment strategies in pediatric clinical trials.  We observed several 
important findings: (1) enrichment is a common feature in pediatric trials, with the vast majority 
of trials included in our cohort incorporating at least one enrichment strategy for patient 
selection; (2) in general, prognostic enrichment strategies were the most commonly used; (3) the 
highest trial success rates were observed when all three enrichment approaches (practical, 
predictive, prognostic) were used in a single trial; and (4) the rate of trial success was higher for 
those trials that employed an enrichment design compared to trials that did not contain any 
enrichment maneuvers. 
The high frequency of use of enrichment strategies in pediatric drug development that we 
observed could be the result of several factors.  In general, pediatric drug development 
temporally follows adult drug development.  During adult drug development, significant 
knowledge is gained about variability in the investigational drug response, variability in placebo 
(or control) response, performance of the primary and secondary clinical trial endpoints, effect 
sizes, tolerability, and dose- or exposure-response relationships.  Furthermore, more mechanistic 
or disease understanding can emerge during the lag between adult and pediatric development 
programs.  As this knowledge accumulates, more informed clinical trials can be designed and 
conducted in subsequent populations of interest, including in pediatric populations. 
In our analysis, prognostic enrichment was generally the most common type of 
enrichment (after accounting for universally employed practical enrichment strategies as 
described in Methods above).  Specifically, over 55% of the 76 programs evaluated used at least 
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predictive and practical enrichment, respectively.  Additionally, prognostic enrichment was over-
represented (~45%) in clinical trials that employed a single enrichment strategy compared with 
those that used predictive (~38%) or practical (~17%) enrichment as their single enrichment 
approach.  The more frequent use of prognostic enrichment may reflect greater knowledge of and 
confidence around the risk factors associated with the clinical events of interest in the diseases 
studied compared with our generally limited understanding of clearly identifiable predictors of 
drug response.   
Interestingly, the majority of development programs not only used enrichment 
approaches, but often used multiple enrichment approaches simultaneously.  When looking at 
trials that used more than one enrichment approach, trials that employed all three strategies (i.e., 
practical, prognostic, and predictive) demonstrated nominally greater success rate (approaching 
90%) compared with those that employed any two strategies in combination (success rates 
ranged from 75-79%).  The ability to use all three enrichment approaches may be indicative of a 
more holistic understanding of 1) the determinants of drug response variability, 2) disease 
mechanism and manifestation in pediatric populations, and 3) other sources of non-drug related 
variability.  A thorough assessment of these factors, if known, prior to the conduct of clinical 
trials in pediatric populations is prudent, and should be documented and disseminated when 
possible to enable pediatric drug development across a wide range of therapeutic areas. 
Of critical importance, our data suggest that use of any type of enrichment approach is 
more likely to lead to clinical trial and development program success compared to not using 
enrichment as part of clinical trial design and execution.  Clinical trials that used enrichment 
were 1.24 times more likely to successfully meet their pre-specified primary endpoint compared 
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clinical trial does seem to be an important determinant of clinical trial success in pediatric drug 
development.     
Prior to our analysis, there had been anecdotal evidence that enrichment strategies in 
specific pediatric patient populations could lead to drug development success and approval of 
treatment in diseases that had historically shown failure. For example, in the case of development 
of drugs to treat migraine headaches in adolescents, early clinical trials all failed between 1999 
and 2003. Root cause analyses revealed that the high placebo response rate in this population 
was a major driver of clinical trial failure.  Consequently, more recent trials employed an 
enrichment approach that double-randomized patients and dropped placebo responders after the 
first randomization, leading to successful trials of drugs in adolescent migraine headache.(7) 
Another example of the use of enrichment strategies in specific patient populations is the study 
of oxybutynin for pediatric neurogenic bladder dysfunction.  A predictive enrichment strategy 
was employed in this trial which involved the inclusion of pediatric patients who were current 
users of oxybutynin and had previously responded to and tolerated the drug, and therefore were 
more likely to respond to treatment.  Patients who experienced adverse effects or did not respond 
to oxybutynin were excluded from the trial.(6)  Our systematic review lends support to these 
anecdotal cases in which enrichment strategies increased the likelihood for pediatric clinical trial 
success. 
Our current analysis is not without limitations.  First, our cohort is comprehensive for the 
time period evaluated (2012-2016).  Notwithstanding, the cohort consisted of studies submitted 
to the FDA during this time period, not necessarily conducted during this time period.  In fact, 
the studies were in large part designed and executed prior to 2012.  Consequently, we were not 
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strategies in pediatric trials.  Second, while comprehensive for the time period evaluated, the 
relatively small number of trials within some of the therapeutic areas listed limits the ability to 
make definitive conclusions about the utility of enrichment strategies in specific therapeutic 
areas.  Third, a number of other factors are known to influence clinical trial outcome; these 
include, but are not limited to, appropriateness of the dosing regimen tested and definition and 
ascertainment of the primary endpoint studied.  A multidimensional evaluation of all factors that 
could be associated with clinical trial success or failure was beyond the scope of our present 
work, and may not ultimately be feasible given the limited sample of trials and development 
programs.  Nonetheless, the totality of the data suggests the importance of enrichment as a 
consideration in pediatric clinical trial planning.    
 In conclusion, our review of 112 pediatric drug development trials in 76 drug 
development program from 2012-2016 identified extensive use of practical, prognostic, and 
predictive enrichment strategies in pediatric drug development. The combined use of multiple 
enrichment strategies was common, but some programs used no enrichment strategies.  In 
general, the use of enrichment strategies was associated with successful pediatric trials and 
programs. The use of enrichment in pediatric drug development programs, where patients are 
often limited and ethical concerns also restrict enrollment of pediatric patients, should continue 
to be encouraged.  To the extent possible, enrichment designs should be explicitly considered in 
protocol development and clinical trial execution in pediatric drug development.   
Methods 
We surveyed pediatric efficacy trials from drug development programs submitted to FDA under 
the Food and Drug Administration Safety and Innovation Act (FDASIA, July, 2012 – July, 
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pediatric population were reviewed as part of this survey. For each trial and drug product, the 
pediatric protocols, publically available FDA reviews,(8, 9) and the product labels(10) were 
reviewed.  
FDA-authored reviews of each trial and the trial protocols were used to extract the 
following data: drug name, proposed indication (i.e., pediatric condition for which the approval 
was being sought), FDA therapeutic review area, enrichment strategy(ies) used, trial outcome 
and drug approval status.   
Enrichment strategies were categorized broadly as practical, predictive, or prognostic.  
Strategies were subsequently further subcategorized as outlined in the 2012 FDA draft Guidance 
for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and 
Biological Products (Table 1).(3) The classification of enrichment strategies used in pediatric 
drug development programs was adjudicated by three authors and disagreements were resolved 
by consensus. Universally employed practical enrichment strategies, such as the exclusion of 
patients with hypersensitivities to the drug under study, with concomitant illnesses likely to lead 
to drop-out or death, or who are taking drugs that pharmacologically similar to or likely to 
interact with the study drug, were not included in the analysis. 
Trial outcome was categorized as a success or failure based upon whether or not the trial 
achieved statistical significance on its primary efficacy endpoint.  Drug approval status was 
categorized as approved or not approved based upon whether the pivotal trial(s) resulted in an 
FDA-approved indication for use of the drug in the pediatric population studied.   
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tStudy Highlights (150 words – excluding question as per author guide) 
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
o Clinical trial enrichment involves prospectively incorporating trial design 
elements that increase the probability of detecting a treatment effect, and an FDA 
guidance for enrichment is available. 
- WHAT QUESTION DOES THIS STUDY ADDRESS? 
o Pediatric drug development is a new science, and the use of enrichment strategies 
in pediatric drug development has not been systematically assessed. 
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? 
o The highest trial success rates were achieved when all three enrichment strategies 
(practical, predictive, and prognostic) were used together within a single trial 
(87.5%), while the lowest success rate was observed when no enrichment strategy 
was used (65.4%). The use of enrichment strategies in pediatric trials was found 
to be associated with trial and program success in our analysis. 
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE? 
o The use of practical, prognostic and predictive enrichment strategies in designing 
pediatric drug development studies is a critical part of increasing clinical trial 
success, and should be formulated with the same rigor as other parts of pediatric 
trial design. 
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tTable 1.  Enrichment strategies *  
 
Strategy Enrichment Approach Description 
Practical Pre-randomization compliance Prior to randomization, 
identifying and selecting 
patients likely to comply with 
treatment  
 Placebo run-in (placebo 
responder) 
Using a lead-in period prior to 
randomization to eliminate 
patients  who improve 
spontaneously or have large 
placebo responses 
 Including only patients with 
consistent baseline values 
Enrolling only patients who 
have consistent baseline 
values (e.g. blood pressure 
measurements, pulmonary 
function tests) 
Prognostic  Medical history Selecting patients with a 
greater likelihood of having an 
event (endpoint) based on 
their medical history 
 Clinical / laboratory 
measurement 
Selecting patients with a 
greater likelihood of having an 
event  based on a clinical or 
laboratory measurement 
 Genomic / proteomic 
measurement 
Selecting patients with a 
greater likelihood of having an 
event based on genomic or 
proteomic measures 
Predictive Active run-in or history of 
response to the medication  
Selecting patients with a past 
history of response to the 
particular intervention under 
study either based on past 
history of use or using an 
active run-in period during the 
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 Randomized withdrawal 
design 
Selecting patients who have an 
apparent response to treatment 
in an open-label period or in 
the treatment arm of a 
randomized trial are 
randomized to continued drug 
treatment or placebo 
 Includes only poor responders 
to alternative therapy  
Selecting patients who have 
been non-responders or are 
intolerant to another drug and 
then randomizing them to the 
new or the original drug (the 
comparison is enriched 
because the population is 
expected to have a poor 
response or a high rate of 
intolerance to the original drug 
compared to the test drug) 
 Includes responders to drugs 
in the same class 
Select patients who have a 
history of responding to drugs 
in the same class as the new 
drug under study 
 Pathophysiologic  Selecting patients based on the 
patient’s individual 
physiology or on assessment 
of disease pathophysiology 
that suggests that only certain 
patient subgroups will respond 
to a particular therapy or that 
certain subgroups will respond 
better than others 
 Genomic  Selecting patients with a 
genomic or proteomic 
characteristic that is related to 
the study drug’s mechanism 
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t Antiviral  / antibiotic resistance Pre-randomization sensitivity testing to identify and enroll 
patients whose organism is 
sensitive to the antibacterial 
drug 
 
*Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs 
and Biological Products. US Food and Drug Administration; 2012. 
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tTable 2.  Therapeutic area, trial outcome, and program outcome.* 
 
Therapeutic  Trial,  Trial   Program, Program 
Area   N  success, N (%) N  success
†
, N (%) 
Anti-infectives 12  12 (100.0%)  6  6 (100.0%) 
Antiviral   15  15 (100.0%)  11  11 (100.0%) 
Dermatology  4  4 (100.0%)  3  3 (100.0%) 
Hematology   4  4 (100.0%)  3  3 (100.0%) 
Imaging   1  1 (100.0%)  1  1 (100.0%) 
Inborn error   1  1 (100.0%)  1  1 (100.0%) 
Neurology  11  9 (81.8%)  6  5 (83.3%) 
Allergy  8  6 (75.0%)  5  4(80.0%) 
GI    5  3 (60.0%)  5  4 (80.0%) 
Analgesia/ 
Anesthesia  6  2 (33.3%)  3  2(66.7%) 
Pulmonary   19  17 (89.5%)  9  6 (66.7%) 
Psychiatry   19  12 (63.2%)  16  10 (62.5%) 
Oncology   4  1 (25.0%)  4  1 (25.0%) 
Cardio-renal   1  0 (0.0%)  1  0 (0.0%) 
Ophthalmology  2  0 (0.0%)  2  0 (0.0%) 
TOTAL   112  87 (77.7%)  76  57 (75.0%) 
_______________________________________________________________________ 
*
Rank ordered by program success 
†
Program success was defined as a program that resulted in an FDA-approved indication for use 
of the drug in the pediatric population studied 
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tTable 3.  Therapeutic area, enrichment strategies employed, and trial outcomes. 
 
Therapeutic  Practical Prognostic Predictive Trial success 
Area (N
*
)  Strategy, N
†
 Strategy, N
†
 Strategy, N
†
 N
* 
(%)_____          
Anti-infectives (12) 0  4  4  12 (100.0%) 
Antiviral (15)  1  1  6  15 (100.0%) 
Dermatology (4) 0  2  0  4 (100.0%) 
Hematology (4) 2  4  2  4 (100.0%) 
Imaging (1)  0  0  0  1 (100.0%) 
Inborn error (1) 1  0  1  1 (100.0%) 
Pulmonary (19) 17  18  12  17 (89.5%) 
Neurology (11) 10  11  1  9 (81.8%) 
Allergy (8)  8  8  2  6 (75.0%) 
Psychiatry (19) 10  12  13  12 (63.2%) 
GI (5)   0  2  0  3 (60.0%) 
Analgesia/ 
Anesthesia (6)  0  3  2  2 (33.3%) 
Oncology (4)  0  1  1  1 (25.0%) 
Cardio-renal (1)  0  0  0  0 (0.0%) 
Ophthalmology (2) 0  0  0  0 (0.0%) 
TOTAL (112)  49  66  44  87 (77.7%) 
_______________________________________________________________ 
* Number of trials 
†
Number of strategies 
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tTable 4.  Overall trial success rates by enrichment strategies employed. 
 
Enrichment strategy   Total trials Trial success Success rate % 
Practical + Prognostic + Predictive  16  14  87.5 
Practical + Prognostic    24  19  79.2 
Practical + Predictive    4  3  75.0 
Prognostic + Predictive   13  10  76.9 
Practical only     5  4  80.0 
Prognostic only    13  10  76.9 
Predictive only    11  10  90.9 
Any strategy      86  70  81.4 
No enrichment strategy   26  17  65.4 
TOTAL     112  87  77.7 
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